Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPEROR phase 3 trial of zorevunersen in pediatric Dravet syndrome
jRCT2071250035Phase 3Active, not recruiting
- Sponsor
- Stoke Therapeutics
- Start
- Nov 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of zorevunersen in Dravet syndrome (2 arms), sponsored by Stoke Therapeutics. Primary endpoint: Measurement of Seizure Reduction at Week 28. Started Nov 2025; status: active, not recruiting.
02
Drugs
zorevunersen
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on jRCT2071250035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250035.